Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy
Min Hye Noh(The University of Texas Health Science Center), Ji Young Yoo(The University of Texas MD Anderson Cancer Center), Zhongming Zhao(Vanderbilt University), Jin Muk Kang(The University of Texas Health Science Center at Houston), Kimberly Rivera-Caraballo(The University of Texas Health Science Center), Ji Seon Shim(The University of Texas Health Science Center), Sara A. Murphy(The University of Texas Health Science Center), Yuanqing Yan(Northwestern University), E. Antonio Chiocca(Center for Cancer Research), Balveen Kaur(Augusta University), Yoshihiro Otani(Okayama University), Hiroshi Nakashima(Brigham and Women's Hospital), Seung‐Hee Yoo(The University of Texas Health Science Center), Yeshavanth Banasavadi‐Siddegowda(Neurological Surgery), Grace Nguyen(The University of Texas Health Science Center), Alberto J Bueso-Perez(The University of Texas Health Science Center), Eunju Kim(University of Nebraska–Lincoln), Alexandra Miller(Mayo Clinic), Minxin Huang(The University of Texas Health Science Center), Tae Jin Lee(Augusta University)
Cited by 22
Related Papers
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
|Nature|2018|1.5k
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
|Cell Reports|2018|1.3k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Decreased extra-renal urate excretion is a common cause of hyperuricemia
|Nature Communications|2012|703
Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
|Science Advances|2018|614